ClinicalTrials.gg
CompletedNCT05590884Updated Oct 28, 2025Results posted

Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age

A Phase 2 interventional study of Gadopiclenol in Central Nervous System Diseases, Pediatric Disorder and Body Indication, sponsored by Guerbet. Completed at 11 sites in 3 countries. Open to participants aged Up to 23 Months. Per ClinicalTrials.gov, last updated 2025-10-28.

Sponsored by Guerbet · Phase 2, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
Up to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Central Nervous System Diseases with a site in Poland — 1 open to participants now, 3 under way, 2 of them phase 3. Central Nervous System Diseases · Poland.

Enrollment
21st of 22
36 · median 286
Started
2022
with 2 others
Phase 2
7 of 22
1 open now
Registered
19th of 22
by date
Lead sponsor
1 of 22
Guerbet

Among the 22 studies in Central Nervous System Diseases with a site in Poland, this one is the 21st largest by enrollment, is one of 3 that started in 2022, is one of 7 in phase 2, and was the 19th registered.

Central Nervous System Diseases

386 studies on the registry are indexed under Central Nervous System Diseases; 104 are open to participants now.

Browse Central Nervous System Diseases studies →

Open to participants now

1 of the 22 studies in Central Nervous System Diseases with a site in Poland is open now. Recruiting first, the newest first:

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 75 Central Nervous System Diseases studies recruiting now, 34 (45%) set no upper age limit and 21 (28%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: Up to 23 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Central Nervous System Diseases with a site in Poland, or all of them as a file.
02

Study summary

This Phase II open-label, uncontrolled, multicenter trial is designed to investigate the pharmacokinetic (PK) profile of gadopiclenol in plasma, in pediatric patients aged up to 23 months inclusive (term neonates or preterm infants after the neonatal period), using a population PK approach.

Primary objective is to evaluate the PK profile of gadopiclenol in plasma following single intravenous injection of 0.05 mmol/kg body weight (BW) in pediatric population aged up to 23 months (inclusive) scheduled for a contrast-enhanced MRI examination of any body region including central nervous system (CNS).

Read the detailed description

Three age groups are defined:

  • Group 1: patients aged 3 to 23 months (inclusive)
  • Group 2: patients aged 28 days to less than 3 months;
  • Group 3: patients aged from birth to 27 days (term newborns).

At study set-up, the inclusions started with the oldest patients in group 1 and using an age-down staggered approach.

The decision to start the inclusions in group 2 was taken by the Trial Safety Review Board based on safety assessment over one-day period after injection of the first 13 patients in group 1.

According to the protocol version 4 (amendments 2 \& 3), the age-down staggered approach was discontinued to allow the inclusions in Group 3 (patients aged from birth to 27 days), simultaneously to inclusions in group 1 and group 2.

A total of 3 blood samples per patient were taken post-injection for PK analysis.

03

Conditions studied

  • Central Nervous System Diseases
  • Pediatric Disorder
  • Body Indication
04

Who can participate

Ages eligible
Up to 23 Months
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Female or male pediatric patient aged from birth to 23 months of age inclusive (term neonates for all age groups or preterm infants after the neonatal period for groups 1 or 2). The neonatal period for preterm newborns is defined as the day of birth through the expected date of delivery plus 27 days. Term is defined as ≥37 completed weeks of amenorrhea,
  2. Patient with known or highly suspected abnormalities/ lesion(s), scheduled to undergo contrast-enhanced MRI of any body region including CNS [...]

Main Exclusion Criteria:

  1. Patient planned for treatment or procedure (e.g. surgery) that would prevent from obtaining the required blood samples or performing other trial procedures between the screening visit and up to one day after gadopiclenol administration,
  2. Patient undergoing treatment or procedure (e.g., diuretics, blood loss or blood transfusion) preceding or subsequent to gadopiclenol administration that would alter gadopiclenol pharmacokinetic parameters,
  3. Patient with acute or chronic renal insufficiency defined as estimated (eGFR) out of age-adjusted normal value calculated based on bedside Schwartz equation, [...]

9. Patient undergoing a change in chemotherapy (product or dosage) within one day prior to or one day after gadopiclenol administration, 10. Patient who received or will receive any other contrast agent for CT and/or MRI within one week prior to or one week after gadopiclenol administration, 11. Patient with for MRI such as iron metal implants (e.g., aneurysm clips, pacemaker), 12. Patient with history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents [...]

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Age Group 1: patients aged 3 to 23 months

    One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.

    Drug: Gadopiclenol

  • Experimental
    Age Group 2: patients aged 28 days to less than 3 months

    One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.

    Drug: Gadopiclenol

  • Experimental
    Age Group 3: patients aged from birth to 27 days (term newborns)

    One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.

    Drug: Gadopiclenol

Interventions

  • Patients will receive a single dose of gadopiclenol calculated according to their BW on the day of MRI examination. Gadopiclenol will be administered at a dose of 0.05 mmol/kg BW (0.1 mL/kg BW).

    Also known as: Elucirem

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUCinf)

    Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg

    Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours)

  2. Elimination Half-life (t1/2α)

    Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg

    Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).

  3. Terminal Half-life (t1/2β)

    Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg

    Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).

  4. Gadopiclenol Concentrations 10 Min Post-injection (C10 Min)

    Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg

    Time frame: blood sample collection 10 minutes post-injection of gadopiclenol for analysis

  5. Gadopiclenol Concentration 20 Min Post-injection (C20 Min)

    Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg

    Time frame: blood sample collection 20 minutes post-injection of gadopiclenol

  6. Gadopiclenol Concentrations 30 Min Post-injection (C30 Min)

    Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg

    Time frame: blood sample collection 30 minutes post-injection of gadopiclenol

  7. Clearance

    Individual predicted final model parameter scaled by body weight

    Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).

  8. Central Volume of Distribution (V1)

    Individual predicted final model parameter scaled by body weight

    Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).

  9. Inter-compartment Clearance (Q)

    Individual predicted final model parameter scaled by body weight

    Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).

  10. Peripheral Volume of Distribution (V2)

    Individual predicted final model parameter scaled by body weight

    Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).

07

Results

Posted Oct 28, 2025
Limitations and caveats
Due to incomplete recruitment in study GDX-44-015, with only 2 patients aged 28-89 days and none aged less than 28 days who could be included in the popPK analysis, exposure in these groups was only obtained by simulation using the final model.

Participant flow

Participant flow — Overall Study
MilestoneAge Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)
Started3321
Completed3221
Not completed100
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryArea Under the Curve (AUCinf)

Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg

Time frame:
A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours)
Reported as:
Geometric mean · h.mg/L
Area Under the Curve (AUCinf)
h.mg/LAge Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)
Area Under the Curve (AUCinf)392.3 ± 27.6493.3 ± 9.9—
PrimaryElimination Half-life (t1/2α)

Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg

Time frame:
A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).
Reported as:
Geometric mean · h
Elimination Half-life (t1/2α)
hAge Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)
Elimination Half-life (t1/2α)0.3 ± 30.30.3 ± 30.3—
PrimaryTerminal Half-life (t1/2β)

Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg

Time frame:
A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).
Reported as:
Geometric mean · h
Terminal Half-life (t1/2β)
hAge Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)
Terminal Half-life (t1/2β)1.5 ± 21.42.1 ± 8.4—
PrimaryGadopiclenol Concentrations 10 Min Post-injection (C10 Min)

Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg

Time frame:
blood sample collection 10 minutes post-injection of gadopiclenol for analysis
Reported as:
Geometric mean · mg/L
Gadopiclenol Concentrations 10 Min Post-injection (C10 Min)
mg/LAge Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)
Gadopiclenol Concentrations 10 Min Post-injection (C10 Min)226.8 ± 15.8190.4 ± 16.2—
PrimaryGadopiclenol Concentration 20 Min Post-injection (C20 Min)

Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg

Time frame:
blood sample collection 20 minutes post-injection of gadopiclenol
Reported as:
Geometric mean · mg/L
Gadopiclenol Concentration 20 Min Post-injection (C20 Min)
mg/LAge Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)
Gadopiclenol Concentration 20 Min Post-injection (C20 Min)161.5 ± 17.2149.8 ± 13.4—
PrimaryGadopiclenol Concentrations 30 Min Post-injection (C30 Min)

Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg

Time frame:
blood sample collection 30 minutes post-injection of gadopiclenol
Reported as:
Geometric mean · mg/L
Gadopiclenol Concentrations 30 Min Post-injection (C30 Min)
mg/LAge Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)
Gadopiclenol Concentrations 30 Min Post-injection (C30 Min)109.4 ± 22.4116.2 ± 13.3—
PrimaryClearance

Individual predicted final model parameter scaled by body weight

Time frame:
A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).
Reported as:
Mean · L/h/kg
Clearance
L/h/kgAge Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)
Clearance0.128 ± 0.0350.097 ± 0.004—
PrimaryCentral Volume of Distribution (V1)

Individual predicted final model parameter scaled by body weight

Time frame:
A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).
Reported as:
Mean · L/kg
Central Volume of Distribution (V1)
L/kgAge Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)
Central Volume of Distribution (V1)0.176 ± 0.0330.214 ± 0.03—
PrimaryInter-compartment Clearance (Q)

Individual predicted final model parameter scaled by body weight

Time frame:
A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).
Reported as:
Mean · L/h/kg
Inter-compartment Clearance (Q)
L/h/kgAge Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)
Inter-compartment Clearance (Q)0.099 ± 0.0250.123 ± 0.029—
PrimaryPeripheral Volume of Distribution (V2)

Individual predicted final model parameter scaled by body weight

Time frame:
A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).
Reported as:
Mean · L/kg
Peripheral Volume of Distribution (V2)
L/kgAge Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)
Peripheral Volume of Distribution (V2)0.066 ± 0.0140.066 ± 0.003—

Adverse events

Collected over Adverse events (AE) occurring from the beginning of patient's participation in the trial (Informed Consent Form signature) until the end of the participation (up to 3 months following gadopiclenol administration).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Age Group 1: Patients Aged 3 to 23 Months0/33 (0%)8/33 (24.2%)13/33 (39.4%)
Age Group 2: Patients Aged 28 Days to Less Than 3 Months0/2 (0%)0/2 (0%)2/2 (100%)
Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns)0/1 (0%)0/1 (0%)0/1 (0%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventAge Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)
Feeding DisorderMetabolism and nutrition disorders1/330/20/1
Tumour ExcisionSurgical and medical procedures1/330/20/1
PyrexiaGeneral disorders1/330/20/1
Microcytic AnaemiaBlood and lymphatic system disorders1/330/20/1
Gastroenteritis NorovirusInfections and infestations1/330/20/1
Pneumonia Parainfluenzae ViralInfections and infestations1/330/20/1
BronchitisInfections and infestations1/330/20/1
Cerebral CystNervous system disorders1/330/20/1
Intracranial Pressure IncreasedNervous system disorders1/330/20/1
Device MalfunctionProduct Issues1/330/20/1
Most frequent other events
Showing 10 of 23
Most frequent other events
EventAge Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)
HypertensionVascular disorders0/331/20/1
Aspartate Aminotransferase IncreasedInvestigations0/331/20/1
Serum Ferritin IncreasedInvestigations0/331/20/1
VomitingGastrointestinal disorders5/330/20/1
Viral Upper Respiratory Tract InfectionInfections and infestations1/330/20/1
ConjunctivitisInfections and infestations1/330/20/1
ParonychiaInfections and infestations1/330/20/1
Hand-Foot-And-Mouth DiseaseInfections and infestations1/330/20/1
AnxietyPsychiatric disorders1/330/20/1
ChokingRespiratory, thoracic and mediastinal disorders1/330/20/1

Baseline characteristics

Baseline analysis population included 36 patients who received one injection of gadopiclenol (safety set): 33 patients aged 3 to 23 months, 2 aged 28 days to less than 3 months and 1 patient aged 0-27 days.

Age, Continuous
Age, Continuous(months)Age Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)Total
Mean13.11 ± 6.221.94 ± 0.140.8 ± NA12.15 ± 6.77
Sex: Female, Male
Sex: Female, Male(Participants)Age Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)Total
Female171018
Male161118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Age Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)Total
Hispanic or Latino1001
Not Hispanic or Latino322135
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Age Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White332136
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Age Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)Total
Hungary101112
United States4105
Poland190019
Weight
Weight(kilogram)Age Group 1: Patients Aged 3 to 23 MonthsAge Group 2: Patients Aged 28 Days to Less Than 3 MonthsAge Group 3: Patients Aged From Birth to 27 Days (Term Newborns)Total
Mean9.40 ± 2.185.10 ± 0.284.50 ± NA9.03 ± 2.44
08

Study locations

11 sites
  • Cincinnatti Childrens Hospital
    Cincinnati, Ohio 45229, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425-8908, United States
  • Semmelweis Egyetem
    Budapest, 1094, Hungary
  • Országos Idegtudományi Intézet
    Budapest, Hungary
  • University of Debrecen Clinical Center Pediatric Department
    Debrecen, Hungary
  • Szpital Uniwersytecki nr 1 im. dr Antoniego Jurasza
    Bydgoszcz, Poland
  • Instytut Centrum Zdrowia Matki Polki
    Lodz, Poland
  • Uniwersytecki Szpital Dzieciecy
    Lublin, Poland
  • Kliniczny Szpital Wojewodzki Nr 2 im. Sw. Jadwigi Krolowej
    Rzeszów, Poland
  • Uniwersyteckie Centrum Kliniczne Warszawskiego
    Warsaw, 02-091, Poland
  • Instytut "Pomnik - Centrum Zdrowia Dziecka"
    Warsaw, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Sep 2024, 24 months.

Results were first posted in Oct 2025, 1 year after primary completion.

Of 37 phase 2 interventional studies under Central Nervous System Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 44. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2022
First posted
Oct 21, 2022
StartActual
Sep 21, 2022
Primary completionActual
Sep 30, 2024
CompletionActual
Sep 30, 2024
Results first posted
Oct 28, 2025
Last update
Oct 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05590884
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Oct 21, 2022
Start date
Sep 21, 2022
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024
Results posted
Oct 28, 2025
Last update
Oct 28, 2025

Study contacts

Donna R Roberts, MD
principal investigator · Medical University of South Carolina, Division of Neuroradiology

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadopiclenol

Start the discussion